Shimadzu DryLab - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Shimadzu DryLab


Powerful team for excellent separation and Design Space modeling DryLab & Shimadzu UHPLC

Method registration and validation requires detailed results concerning stability and robustness according to a design space. The well-known and accepted DryLab* software offers unique tools for supporting method development. Based on defined experiments, the design space of the method is modeled in a 3D cube. Each side represents a combination of parameters (mobile phase composition, temperature and pH) – moving inside this cube, the associated separation is modeled and displayed. Areas with good separation are displayed to visualize the design space of this method.

The accuracy of these calculations has been proven by many users. Prediction of retention, using DryLab’s algorithms, matches very well with real results. The design space model adds real value by providing a framework for small method adaptation, which makes it easier to adapt parameters based on new columns, detection or instrumentation as long these changes are executed within the given ‘space’.

Shimadzu’s UHPLC system is controlled via a software interface to LC solution software, methods can be set in PeakMatch and data files are read directly.

(*DryLab is a product of the Molnár Institute of applied chromatography Berlin)

For further details please visit www.shimadzu.eu

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
9%
All of the above.
45%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing

Click here